Procter & Gamble Health delivered robust financial performance for FY26, with net profit surging 30% and sales rising 16%. The company held its 59th Annual General Meeting on September 3, 2026, where management outlined the drivers behind this growth.

The results reflect a shift to a new fiscal calendar, with FY26 covering April 1, 2025, to March 31, 2026. This period was compared against the preceding 12-month window (April 1, 2024, to March 31, 2025) to ensure accurate year-on-year comparability. The previous fiscal year had been a shortened nine-month period due to the calendar change.

What the Numbers Show

The divergence between revenue growth (+16%) and profit growth (+30%) indicates significant operating leverage. Management attributed this margin expansion partly to productivity initiatives, which generated ₹35 crore in savings during FY26. These savings were driven by lean innovation, supply chain efficiencies, and digitization efforts.

Strategic Focus Areas

Management emphasized an integrated growth strategy centered on portfolio performance and consumer superiority. Key product categories driving momentum include Neurobion, Livogen, Evion, and Nasivion. The company also highlighted packaging innovations designed to educate consumers and improve shelf visibility.

Distribution expansion remains a priority, with a focus on leveraging emerging channels such as e-pharmacies and quick-commerce platforms. The company is also extending its reach into extra-urban markets through strengthened distributor partnerships.

Governance and Dividends

Shareholders approved the reappointment of Mr. Aalok Agrawal as a Non-Executive Director and ratified the remuneration for the Cost Auditor for FY27. A special resolution approved the reappointment of Mr. S. Madhavan as a Non-Executive Independent Director for five years, effective November 15, 2026.

The auditors’ report contained no qualifications or observations. The meeting concluded with the declaration of a final dividend for FY26, alongside confirmation of the interim dividend paid earlier in the year.

Procter & Gamble Health has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, to the Bombay Stock Exchange and the National Stock Exchange. The filing, signed by authorized signatory Flavia Peter Machado on August 12, 2026, details the company’s performance across environmental, social, and governance parameters.

Financial Overview

The report discloses a total turnover of ₹1,385 crore and a net worth of ₹524 crore for FY26. Procter & Gamble Health operates primarily in the manufacture and sale of healthcare products, specifically vitamins, minerals, and supplements, which account for 100% of its turnover. Exports contributed 8.24% to the total turnover, with products shipped to five countries during the fiscal year.

Operational Metrics

The company reported a paid-up capital of ₹16.59 crore. Its operations are centered in India, with a registered office in Mumbai and a manufacturing plant in Goa. The entity maintains a pan-India presence across 28 states and eight union territories.

Environmental Impact

Procter & Gamble Health disclosed a total energy consumption of 46,995 GJ for FY26, an increase from 43,509 GJ in FY25. Of this, 29,435 GJ was sourced from renewable sources, while 17,560 GJ came from non-renewable sources. The energy intensity per rupee of turnover decreased slightly to 0.45 GJ/₹ lakhs from 0.47 in the previous year.

Water withdrawal totaled 55,888 kilolitres, down from 57,909 kilolitres in FY25. Groundwater accounted for the majority of withdrawals at 52,665 kilolitres. Total water consumption stood at 26,764 kilolitres. The company discharged 29,124 kilolitres of water, all of which was treated and applied on-site.

Greenhouse gas emissions were reported as follows:

• Scope 1 emissions: 190 metric tonnes of CO2 equivalent (down from 263 in FY25)
• Scope 2 emissions (gross): 3,148 metric tonnes of CO2 equivalent (down from 4,273 in FY25)

Total waste generated increased to 275.41 metric tonnes from 202.35 metric tonnes in FY25. Of this, 138.43 metric tonnes were recycled, and 87.98 metric tonnes were disposed of through coprocessing. The Goa plant remains a zero-manufacturing-waste-to-landfill site.

Employee Welfare and Safety

As of March 31, 2026, the company employed 221 permanent employees and 1,055 permanent workers. Female representation among permanent employees was 27%, while it stood at 10% among permanent workers. The Board of Directors includes two women, representing 28.57% of the total board strength.

Spending on employee well-being measures rose to 0.50% of total revenue from 0.25% in FY25. The company provided health insurance and accident insurance coverage to 100% of its permanent employees and workers. No fatalities or high-consequence work-related injuries were reported during FY26. One recordable work-related injury each was recorded for employees and workers, compared to nil in the previous year.

Governance and Compliance

Procter & Gamble Health adopted the parent company’s Worldwide Business Conduct Manual as its business responsibility policy. The Audit Committee reviews the vigil mechanism report quarterly, while the Board reviews statutory compliance on the same frequency. No material fines, penalties, or regulatory actions were recorded during the fiscal year. Four complaints related to sexual harassment were received, with one upheld and resolved within 90 days.